Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
The European Commission has approved tislelizumab (Tizveni) as a treatment for patients with non–small cell lung cancer (NSCLC) in the frontline or second-line setting, according to a press release from developers BeiGene, Ltd.1 Specifically, the agent has …